Clinical and Molecular Hepatology

Papers
(The TQCC of Clinical and Molecular Hepatology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease153
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma137
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma104
Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–201779
Novel biomarkers for the management of chronic hepatitis B78
Obesity and the risk of primary liver cancer: A systematic review and meta-analysis75
Global incidence and prevalence of nonalcoholic fatty liver disease71
Recent updates on the management of autoimmune hepatitis71
The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future68
Application of transient elastography in nonalcoholic fatty liver disease68
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop65
Current understanding of primary biliary cholangitis64
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications63
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach63
<i>Lactobacillus</i> attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis63
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?63
Managing liver cirrhotic complications: Overview of esophageal and gastric varices56
MAFLD: How is it different from NAFLD?55
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region52
Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial49
Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH49
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals48
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease47
Programmed cell death in alcohol-associated liver disease46
Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging45
KASL clinical practice guidelines for management of chronic hepatitis B43
Autophagy and liver cancer43
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease43
Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients43
Switching to systemic therapy after locoregional treatment failure: Definition and best timing40
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology39
Recent advances in nonalcoholic fatty liver disease metabolomics39
Hepatic Hippo signaling inhibits development of hepatocellular carcinoma39
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name39
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy39
Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects38
The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma38
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease37
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective37
Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry34
RNA interference as a novel treatment strategy for chronic hepatitis B infection34
The effect of moderate alcohol drinking in nonalcoholic fatty liver disease33
Scaling up the in-hospital hepatitis C virus care cascade in Taiwan32
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment32
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease31
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis30
COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis30
Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma30
Changes in the epidemiology and management of bacterial infections in cirrhosis30
Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway30
Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases29
Drug induced liver injury: East versus West – a systematic review and meta-analysis29
The management of post-transplantation recurrence of hepatocellular carcinoma28
Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights27
Hepatocellular carcinoma statistics in South Korea26
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus26
From intestinal dysbiosis to alcohol-associated liver disease25
β-blockers in advanced cirrhosis: More friend than enemy24
Fecal microbiota transplantation in alcohol related liver diseases24
Anti-fibrotic treatments for chronic liver diseases: The present and the future24
Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma24
Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults23
Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding23
Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea23
Global and regional impacts of alcohol use on public health: Emphasis on alcohol policies22
Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir22
Non-alcoholic fatty liver disease: Definition and subtypes22
Alcohol and hepatocarcinogenesis22
Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance21
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma21
Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma21
Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake20
Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort20
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis20
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly20
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective19
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B19
Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma19
Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study19
Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years18
Risk factors in nonalcoholic fatty liver disease18
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases18
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways17
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance17
Interaction between sarcopenia and nonalcoholic fatty liver disease17
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound17
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease17
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection17
Screening strategy for non-alcoholic fatty liver disease16
Emerging medical therapies for severe alcoholic hepatitis16
New next-generation microwave thermosphere ablation for small hepatocellular carcinoma15
The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls15
Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study15
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients15
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults15
The latest global burden of liver cancer: A past and present threat14
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases14
Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma14
Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 414
Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis14
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region14
Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B14
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease14
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases14
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis13
Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease13
Alcohol associated liver cirrhotics have higher mortality after index hospitalization: Long-term data of 5,138 patients13
Comparison between obese and non-obese nonalcoholic fatty liver disease13
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Diseas13
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future13
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives13
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity13
Metabolic disease as a risk of hepatocellular carcinoma13
0.040418863296509